BR112022007417A2 - Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona - Google Patents

Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona

Info

Publication number
BR112022007417A2
BR112022007417A2 BR112022007417A BR112022007417A BR112022007417A2 BR 112022007417 A2 BR112022007417 A2 BR 112022007417A2 BR 112022007417 A BR112022007417 A BR 112022007417A BR 112022007417 A BR112022007417 A BR 112022007417A BR 112022007417 A2 BR112022007417 A2 BR 112022007417A2
Authority
BR
Brazil
Prior art keywords
morpholinoazetidin
dioxopiperidin
fluoro
benzyl
amino
Prior art date
Application number
BR112022007417A
Other languages
English (en)
Inventor
Soraya Carrancio Anton Maria
J Buchholz Tonia
Kasibhatla Shailaja
Lopez-Girona Antonia
Krishna Narla Rama
POURDEHNAD Michael
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112022007417A2 publication Critical patent/BR112022007417A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO DE TRATAMENTO DE MALIGNIDADES HEMATOLÓGICAS USANDO 2-(2,6-DIOXOPIPERIDIN-3-IL)-4-((2-FLUORO-4-((3-MORFOLINOAZETIDIN-1-IL) METIL)BENZIL) AMINO)SOPNDOLINA-1,3-DIONA. São fornecidos aqui métodos de uso de 2-(2,6-dioxopiperi¬din-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)iso¬indolina-1,3-diona, ou um enantiômero, uma mistura de enantiômeros, um tautômero, um isotopólogo, ou um sal farmaceuticamente do mesmo, para tratamento, prevenção ou controle de malignidades hematológicas.
BR112022007417A 2019-10-21 2020-10-20 Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona BR112022007417A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924028P 2019-10-21 2019-10-21
PCT/US2020/056408 WO2021080935A1 (en) 2019-10-21 2020-10-20 Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
BR112022007417A2 true BR112022007417A2 (pt) 2022-07-12

Family

ID=73449175

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007417A BR112022007417A2 (pt) 2019-10-21 2020-10-20 Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona

Country Status (21)

Country Link
US (2) US11666579B2 (pt)
EP (1) EP4048278B1 (pt)
JP (1) JP2022552882A (pt)
KR (1) KR20220103722A (pt)
CN (2) CN115087448A (pt)
AU (1) AU2020372330A1 (pt)
BR (1) BR112022007417A2 (pt)
CA (1) CA3154504A1 (pt)
DK (1) DK4048278T3 (pt)
ES (1) ES2967929T3 (pt)
FI (1) FI4048278T3 (pt)
HR (1) HRP20231487T1 (pt)
HU (1) HUE064768T2 (pt)
IL (1) IL292266A (pt)
LT (1) LT4048278T (pt)
MX (1) MX2022004683A (pt)
PL (1) PL4048278T3 (pt)
PT (1) PT4048278T (pt)
RS (1) RS64936B1 (pt)
SI (1) SI4048278T1 (pt)
WO (1) WO2021080935A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4048278T3 (fi) * 2019-10-21 2023-12-19 Celgene Corp Menetelmiä hematologisten syöpien hoitamiseksi 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dionia käyttämällä

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566290B (zh) * 2014-10-30 2020-05-22 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
RS64663B1 (sr) 2018-04-23 2023-11-30 Celgene Corp Supstituisana jedinjenja 4-aminoizoindolin-1,3-diona i njihova upotreba u lečenju limfoma
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
FI4048278T3 (fi) * 2019-10-21 2023-12-19 Celgene Corp Menetelmiä hematologisten syöpien hoitamiseksi 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dionia käyttämällä

Also Published As

Publication number Publication date
CN115087448A (zh) 2022-09-20
CN115919871A (zh) 2023-04-07
AU2020372330A1 (en) 2022-05-19
WO2021080935A1 (en) 2021-04-29
PT4048278T (pt) 2024-01-12
EP4048278A1 (en) 2022-08-31
ES2967929T3 (es) 2024-05-06
EP4048278B1 (en) 2023-11-01
RS64936B1 (sr) 2024-01-31
FI4048278T3 (fi) 2023-12-19
US11666579B2 (en) 2023-06-06
SI4048278T1 (sl) 2024-01-31
HRP20231487T1 (hr) 2024-03-01
HUE064768T2 (hu) 2024-04-28
KR20220103722A (ko) 2022-07-22
US20210113577A1 (en) 2021-04-22
PL4048278T3 (pl) 2024-03-18
JP2022552882A (ja) 2022-12-20
IL292266A (en) 2022-06-01
LT4048278T (lt) 2023-12-11
MX2022004683A (es) 2022-05-10
DK4048278T3 (da) 2024-01-08
US20230277548A1 (en) 2023-09-07
CA3154504A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
MX2021012507A (es) Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.
NZ750290A (en) Amino pyrimidine ssao inhibitors
ATE498620T1 (de) 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs
NO20054292L (no) Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
DK1351744T3 (da) Anvendelse af specifikke ErbB4-antagonister til behandling af stenose
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
EA202092830A1 (ru) Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
ECSP19015828A (es) Composiciones para comprimidos
MX2017015921A (es) Metodos para tratar esclerosis multiple.
PH12020500211A1 (en) Methods of treating behavior alterations
BR112022007417A2 (pt) Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona
MA51132A (fr) Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci
EA201890585A1 (ru) Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
MX2022004687A (es) Formas solidas que comprenden (s)-2-(2,6-dioxopiperidin-3-il)-4-(( 2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindol in-1,3-diona y sales de las mismas, y composiciones que comprenden la misma y su uso.
MX2020010085A (es) Formulaciones que contienen péptidos.
AU2022300184A1 (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
MX2022004727A (es) Metodos de tratamiento de la leucemia linfocitica cronica con 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)benzil)amino)isoindolina-1,3-diona.
MX2022004686A (es) Composiciones farmaceuticas que comprenden (s)-2-(2,6-dioxopiperid in-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1- il)metil)bencil)indolin-1,3-diona y metodos de uso de las mismas.
BR112023019943A2 (pt) Métodos de tratamento de linfoma de células b usando terapia combinada
EA202090261A1 (ru) Антипролиферативные соединения и способы их применения
DK1631291T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes
EA201990640A1 (ru) Таблеточные композиции
MX2022001413A (es) Compuesto de pirimidina-5-carboxamida.